# US 2017/0281588 A1 · Compositions and Methods for Treating Epithelial Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281588 A1
- Document ID: US20170281588A1
- Status: Published application
- Kind: A1
- Application number: 15/471,503
- Filed: 2017-03-28
- Published: 2017-10-05
- Earliest claimed: 2016-03-31
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Gil G. MOR; Ayesha ALVERO
- Web page: https://patentgrep.com/patent/US20170281588A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.

## Claims

### Claim 1

A method of treating epithelial cancer in a subject suffering from the cancer, the method comprising administering to the subject in need thereof a therapeutically effective amount of the eutomeric isomer of the compound of formula (I), which is 3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol, or a salt or solvate thereof:

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is at least one selected from the group consisting of: (3S,4R)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol; (3R,4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol; (3S,4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol; and (3R,4R)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol.

### Claim 3 (depends on 1)

The method of claim 1, wherein the epithelial cancer is at least one cancer selected from the group consisting of ovarian, endometrial, pancreatic and renal.

### Claim 4 (depends on 3)

The method of claim 3, wherein the ovarian epithelial cancer comprises at least one selected from the group consisting of a CD44+/MyD88+ ovarian cancer stem cell and CD44−/MyD88− ovarian cancer cell.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering to the subject a therapeutically effective amount of at least one agent selected from the group consisting of an AMPK activator, chemotherapeutic drug, or any salt, solvate, enantiomer, diastereoisomer or tautomer thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the amount of the compound and the amount of the at least one agent administered to the subject are such that at least one of the following applies: (a) administration of the amount of the compound is not therapeutically effective in treating the epithelial cancer in the absence of co-administration of the amount of the at least one agent; and (b) administration of the amount of the at least one agent is not therapeutically effective in treating the epithelial cancer in the absence of co-administration of the amount of the compound.

### Claim 7 (depends on 5)

The method of claim 5, wherein the subject experiences an improved disease outcome when administered the compound and the at least one agent, as compared to the disease outcome when the subject is administered the compound in the absence of the at least one agent or when the subject is administered the at least one agent in the absence of the compound, wherein the disease outcome is at least one selected from the group consisting of survival rate increase, tumor size reduction, and metastatic proliferation reduction.

### Claim 8 (depends on 5)

The method of claim 5, wherein the chemotherapeutic drug is at least one selected from the group consisting of Paclitaxel, Cisplatin, Carboplatin, Topotican and Doxoribicin.

### Claim 9 (depends on 5)

The method of claim 5, wherein the AMPK activator is at least one selected from the group consisting of 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), metformin and 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]-2-furancarboxylic acid.

### Claim 10 (depends on 5)

The method of claim 5, wherein the at least one agent is coformulated with the compound.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject is administered the compound as part of a maintenance treatment after having been treated with at least one chemotherapy.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject has suffered at least one epithelial cancer recurrence.

### Claim 13 (depends on 12)

The method of claim 12, wherein the epithelial cancer recurrence is an ovarian cancer recurrence.

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound is administered to the subject (i) once per day, and every week day; or (ii) once per day, and five days out of every seven week days, with two consecutive rest days wherein the compound is not administered to the subject.

### Claim 15 (depends on 11)

The method of claim 11, wherein the maintenance treatment prevents or delays in the subject at least one selected from the group consisting of epithelial cancer recurrence and epithelial cancer metastasis.

### Claim 16 (depends on 1)

The method of claim 1, wherein the compound is formulated in a pharmaceutical composition as part of a nanoparticle, which is optionally coated with a peptide comprising ArgGlyAsp.

### Claim 17 (depends on 1)

The method of claim 1, wherein the epithelial cancer is at least one selected from the group consisting of recurring and resistant to at least one chemotherapy.

### Claim 18

A pharmaceutical composition comprising an amount of the eutomeric isomer of the compound of formula (I), which is 3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol, or a salt or solvate thereof, and an amount of at least one agent selected from the group consisting of an AMPK activator, chemotherapeutic drug, or a salt or solvate thereof, wherein administration of the composition to a subject suffering from epithelial cancer treats or prevents the cancer.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the subject is female and suffering from ovarian cancer.

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18, wherein the amount of the compound and the amount of the at least one agent in the composition are such that at least one of the following applies: (a) administration of the amount of the compound in the composition is not therapeutically effective in treating the epithelial cancer in the absence of the co-administration of the amount of at least one agent in the composition; and (b) administration of the amount of the at least one agent in the composition is not therapeutically effective in treating the epithelial cancer in the absence of co-administration of the amount of the compound in the composition.

### Claim 21 (depends on 18)

The pharmaceutical composition of claim 18, wherein the subject experiences an improved disease outcome when administered the pharmaceutical composition, as compared to the disease outcome when the subject is administered the amount of the compound in the absence of the amount of the at least one agent or when the subject is administered the amount of the at least one agent in the absence of the amount of the compound, wherein the disease outcome is at least one selected from the group consisting of survival rate increase, tumor size reduction, and metastatic proliferation reduction.
